Ahead of 2 April reciprocal tariff deadline, USTR report red-flags MSP, Make-in-India, high import duties
Ahead of the 2 April deadline for implementing reciprocal tariff, the Office of the United States Trade Representative has raised concerns over India’s trade and investment policies in its 2025 National Trade Estimate Report on Foreign Trade Barriers. The report, which was released on 31 March 2025, cites high tariffs, restrictive digital trade rules, weak intellectual property enforcement, and unfair procurement practices as key obstacles for U.S. businesses. High Tariff Barriers The report notes that India’s average Most-Favored-Nation applied tariff rate stood at 17% in 2023—the highest among major world economies—compared to 13.5% for non-agricultural goods and 39% for agricultural products. Minimum Support Price The NTE report highlights India’s agricultural subsidies, particularly the MSP system for crops like rice and wheat, arguing that these distort global prices and disadvantage U.S. farmers.
‘Welcome relief:’ Experts say Trump’s tariff move may boost India’s pharma, textile industries
India looks for opportunities amid US 27% tariff, vows to push trade deal this year
Discover Related
Countries and companies mull strategies for coping with barrage of higher US tariffs
U.S. tariff imposition: Congress MPs protest; demand answers from government
Trump tariffs could stymie Big Tech's U.S. data center spending spree
US tariffs stay at 26% as White House unveils new trade document
Sensex crashes 1,000 points: 3 reasons behind today's stock market bloodbath
Tariffs in America, your NRI friends might ask you to buy iPhone for them from India
Trump's tariff jitters hit US stocks: Will Sensex, Nifty feel the heat today?
What to know about the Trump tariffs upending global trade and markets
From EU To India, China To Canada: How Countries Responded To Trump's Reciprocal Tariffs
Trump tariffs: India holds fire as US announces tariffs
Boeing aircraft delays, supply chain issues may worsen
‘India’s jewellery exports to U.S. may halve unless bilateral trade pact takes shape’
Indian equities, bonds, currency show resilience amid Trump's tariff tantrum
Time to ‘dump’ WTO, TRIPS: RSS economic wing after Trump’s tariffs announcement
No tariffs on Indian pharma; plays vital role in supplying affordable medicines to US
Indira Rajaraman: US Liberation Day tariffs target the WTO’s playing field
Back to economics 101: How Trump's tariffs disrupt 200 years of trade rules
Trump tariffs: Who is retaliating, who isn’t? How is India responding?